Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NY:AZN)

188.42 +5.02 (+2.74%)

Official Closing Price Updated: 7:00 PM EDT, Mar 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 Next >

AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results

March 27, 2026

AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster...

Via MarketMinute

Topics Intellectual Property

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

March 27, 2026

From AstraZeneca

Via Business Wire

Merck & Co. (MRK) 2026 Analysis: Navigating the Keytruda Cliff with Pipeline-Driven Resilience

March 25, 2026

As of March 25, 2026, Merck & Co., Inc. (NYSE: MRK) stands at a pivotal crossroads in its 135-year history. Known globally as a titan of oncology and vaccines, the Rahway, New Jersey-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush

March 18, 2026

As of March 18, 2026, the corporate landscape has undergone a radical transformation. The era of the sprawling global conglomerate, once the gold standard of industrial stability, is rapidly giving way...

Via MarketMinute

Topics Artificial Intelligence Economy

Could This International ETF Be One of the Best Investments of 2026? ↗

March 14, 2026

International stocks look attractively valued in an expensive market environment.

Via The Motley Fool

Topics ETFs

The 'Sentiment Trap': Why Beating Earnings Is No Longer Enough in the Age of AI Sentiment Analysis

March 13, 2026

In the high-stakes theater of corporate earnings calls, a "beat" on the bottom line used to be a guaranteed ticket to a stock price rally. However, as we move through the first quarter of 2026, a new...

Via MarketMinute

Topics Artificial Intelligence Earnings Regulatory Compliance

The Billion-Dollar Divide: How "Megadeals" Are Defining a K-Shaped M&A Market in 2026

March 11, 2026

The opening months of 2026 have revealed a startling paradox in the global financial landscape: while the sheer number of corporate marriages is dwindling, the price tags on the few remaining...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Pfizer (PFE) 2026 Research Feature: The High-Stakes Pivot to Oncology and Obesity

March 10, 2026

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering...

Via Finterra

Topics Economy Intellectual Property Lawsuit

AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer

March 10, 2026

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer

March 09, 2026

From AstraZeneca

Via Business Wire

The Great Rotation: Why Global Capital is Deserting US Tech for International Value in 2026

March 05, 2026

As of early March 2026, the long-standing dominance of the S&P 500 (NYSEARCA: VOO) has met its most significant challenge in nearly a decade. For the first time since the mid-2010s, international...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Compugen (CGEN) Q4 2025 Earnings Call Transcript ↗

March 02, 2026

Compugen (CGEN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

As Investors Flee U.S. Equities, This Global ETF Is Outperforming ↗

March 02, 2026

Via MarketBeat

Topics ETFs

After a Near 50% Drop, Tempus AI Could Be Ripe for a Rebound ↗

February 27, 2026

Via MarketBeat

Topics Artificial Intelligence

Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy

February 26, 2026

In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI...

Via MarketMinute

Topics Economy Intellectual Property

AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange

February 26, 2026

On February 2, 2026, AstraZeneca PLC (NYSE: AZN) officially rang the opening bell at the New York Stock Exchange, marking the completion of its high-profile transition from the Nasdaq. The move signals...

Via MarketMinute

Topics ETFs

Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics

February 25, 2026

In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total...

Via MarketMinute

Topics Intellectual Property

CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

February 20, 2026

From AstraZeneca

Via Business Wire

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

February 16, 2026

As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that...

Via MarketMinute

Topics Intellectual Property

Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts ↗

February 16, 2026

Goldman Sachs expects European and emerging-market equities to beat the U.S. stock market over the next decade.

Via The Motley Fool

Topics ETFs Stocks

The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind

February 13, 2026

As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

February 13, 2026

From AstraZeneca

Via Business Wire

A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH ↗

February 12, 2026

Via MarketBeat

Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance

February 12, 2026

As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as...

Via Finterra

Topics Economy Intellectual Property

The Great Rebound: 2026 Becomes the Year of the Strategic Mega-Deal as M&A Activity Surges

February 11, 2026

As of February 11, 2026, the corporate landscape is undergoing its most significant transformation in half a decade. After two years of high interest rates and regulatory gridlock that chilled the...

Via MarketMinute

Topics Artificial Intelligence Economy

AstraZeneca awards $3.4 million for programs to improve access to healthcare for patients across the US

February 11, 2026

From AstraZeneca

Via Business Wire

AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse

February 10, 2026

On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the...

Via MarketMinute

Topics Artificial Intelligence Earnings Economy

Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse

February 10, 2026

Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the...

Via Finterra

Topics Economy Intellectual Property

The $80 Billion Ambition: An In-Depth Analysis of AstraZeneca (AZN) in 2026

February 10, 2026

Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British...

Via Finterra

Topics Artificial Intelligence Economy Fraud

Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

February 10, 2026

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

Via FinancialNewsMedia

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.